

# Table of Contents

<i>Chapter</i>		<i>Page</i>
<b>1</b>	<b>Menstrual Cycle: Normal Patterns, Menstrual Disorders, and Menstrually-Related Problems. . . . .</b>	<b>1</b>
	<i>Anita L. Nelson, MD</i>	
	<i>Lee Shulman, MD</i>	
	Assessing the Menstrual Cycle. . . . .	2
	Menstrual Disorders . . . . .	16
	Menstrually Related Problems. . . . .	41
	Menstrual Exacerbation of Other Medical Conditions . . . . .	51
<b>2</b>	<b>Engaging With Unintended Pregnancy Through Patient-Centered Reproductive Goals and Contraceptive Counseling. . . . .</b>	<b>63</b>
	<i>Patty Cason, MS, FNP-BC</i>	
	<i>Abigail R.A. Aiken, MD, MPH, PhD</i>	
	Unintended Pregnancy in the United States . . . . .	64
	Reproductive Goals . . . . .	69
	Contraceptive Counseling. . . . .	77
	A Framework for Counseling. . . . .	79
	Summary . . . . .	90
<b>3</b>	<b>Efficacy, Safety, and Personal Considerations . . . . .</b>	<b>95</b>
	<i>James Trussell, PhD</i>	
	<i>Abigail RA Aiken, MD, MPH, PhD</i>	
	<i>Elizabeth Micks, MD, MPH</i>	
	<i>Katherine A. Guthrie, FRCOG, FFSRH</i>	
	Efficacy: “Will It Work?” . . . . .	98
	Safety: “Will It Hurt Me?” . . . . .	111
	Noncontraceptive Benefits . . . . .	117
	Personal Considerations . . . . .	120
<b>4</b>	<b>Contraceptive Implant . . . . .</b>	<b>129</b>
	<i>Anita L. Nelson, MD</i>	
	<i>Diana Crabtree Sokol, MD</i>	
	<i>Jaelyn Grentzer, MD, MSCI</i>	
	Mechanism of Action. . . . .	130
	Effectiveness . . . . .	130
	Duration of Use . . . . .	133
	Candidates for Implant Use . . . . .	134

<i>Chapter</i>		<i>Page</i>
	Requirements for Implant Providers . . . . .	135
	Advantages . . . . .	135
	Disadvantages . . . . .	138
	Providing the Method . . . . .	142
	Managing Problems and Follow-Up . . . . .	148
	User Instructions . . . . .	150
<b>5</b>	<b>Intrauterine Devices (IUDs) . . . . .</b>	<b>157</b>
	<i>Gillian Dean, MD, MPH</i>	
	<i>Eleanor Bimla Schwarz, MD, MS</i>	
	Mechanism of Action . . . . .	161
	Effectiveness . . . . .	162
	Advantages . . . . .	162
	Disadvantages and Cautions . . . . .	165
	Providing the IUD . . . . .	169
	Managing Problems and Follow-Up . . . . .	177
	User Instructions for Intrauterine Contraception . . . . .	181
<b>6</b>	<b>Injectable Contraceptives . . . . .</b>	<b>195</b>
	<i>Wan-Ju Wu, MD, MPH</i>	
	<i>Deborah Bartz, MD, MPH</i>	
	Mechanism of Action . . . . .	196
	Effectiveness . . . . .	197
	Advantages . . . . .	198
	Disadvantages and Cautions . . . . .	201
	Special Issues . . . . .	206
	Providing DMPA . . . . .	211
	Managing DMPA Problems and Follow-Up . . . . .	213
	User Instructions for DMPA . . . . .	214
<b>7</b>	<b>Contraceptive Patch and Vaginal Contraceptive Ring . . . . .</b>	<b>227</b>
	<i>Kavita Nanda, MD, MHS</i>	
	<i>Anne E. Burke, MD, MPH</i>	
	Contraceptive Patch . . . . .	227
	Vaginal Contraceptive Ring . . . . .	234
	Providing the Contraceptive Patch and Vaginal Ring . . . . .	241
<b>8</b>	<b>Combined Oral Contraceptives (COCs) . . . . .</b>	<b>263</b>
	<i>Carrie Cwiak, MD, MPH</i>	
	<i>Alison B. Edelman, MD, MPH</i>	
	Mechanism of Action . . . . .	265
	Effectiveness . . . . .	268
	Advantages . . . . .	271
	Disadvantages and Cautions . . . . .	276
	Providing the Method . . . . .	282

<i>Chapter</i>		<i>Page</i>
	Managing Problems . . . . .	299
	User Instructions for Combined Oral Contraceptives . . . . .	305
<b>9</b>	<b>Progestin-Only Pills . . . . .</b>	<b>317</b>
	<i>Elizabeth G. Raymond, MD, MPH</i> <i>Daniel Grossman, MD</i>	
	Mechanism of Action . . . . .	318
	Effectiveness . . . . .	318
	Advantages . . . . .	319
	Disadvantages and Cautions . . . . .	320
	Providing the Method . . . . .	322
	Managing Problems and Follow-Up . . . . .	324
	User Instructions for Progestin-Only Pills . . . . .	324
<b>10</b>	<b>Emergency Contraception . . . . .</b>	<b>329</b>
	<i>James Trussell, PhD</i> <i>Kelly Cleland, MPA, MPH</i> <i>Eleanor Bimla Schwarz, MD, MS</i>	
	Mechanism of Action . . . . .	336
	Effectiveness . . . . .	339
	Advantages and Indications . . . . .	344
	Instructions for Using EC . . . . .	355
<b>11</b>	<b>Vaginal Barriers and Spermicides . . . . .</b>	<b>367</b>
	<i>Anita Nelson, MD</i> <i>Bryna Harwood, MD, MS</i>	
	Mechanism of Action . . . . .	368
	Advantages . . . . .	371
	Disadvantages . . . . .	372
	Female Condom (FC2) . . . . .	373
	Caya Diaphragm . . . . .	379
	FemCap Cervical Cap . . . . .	383
	Spermicides . . . . .	388
<b>12</b>	<b>Fertility Awareness-Based Methods . . . . .</b>	<b>395</b>
	<i>Victoria H. Jennings, PhD</i> <i>Chelsea B. Polis, PhD</i>	
	Mechanism of Action . . . . .	396
	Effectiveness . . . . .	398
	Advantages and Indications . . . . .	401
	Disadvantages and Cautions . . . . .	403
	Providing Fertility Awareness-Based Methods . . . . .	405
	User Instructions for Fertility Awareness-Based Methods . . . . .	406

<i>Chapter</i>		<i>Page</i>
<b>13</b>	<b>Abstinence, Noncoital Sex, and Sexual Health: What Every Clinician Needs to Know</b> .....	417
	<i>John S. Santelli, MD, MPH</i>	
	<i>Melissa Kottke, MD, MPH, MBA</i>	
	<i>Stephanie Grilo, MA</i>	
	Sexual Rights and Sexual Expression .....	418
	Definitions and Demographics: Abstinence and Noncoital Sex .....	419
	Effectiveness .....	422
	Sexual Assault .....	422
	Clinical Assessment and Counseling Regarding Abstinence or Other Forms of Sexual Expression .....	423
	Clinician Roles in Comprehensive Sexuality Education Programs .....	425
	User Instructions for Abstinence—for Contraception or STI Protection .....	426
<b>14</b>	<b>Male Condoms</b> .....	431
	<i>Lee Warner, PhD, MPH</i>	
	<i>Markus J. Steiner, PhD, MSPH</i>	
	Mechanism of Action .....	432
	Effectiveness Against Pregnancy .....	434
	Advantages and Indications .....	435
	Disadvantages and Cautions .....	435
	Providing Condoms—Counseling .....	438
	Managing Problems and Follow-Up .....	442
	User Instructions for Condoms .....	443
<b>15</b>	<b>Coitus Interruptus (Withdrawal, Pulling Out)</b> .....	451
	<i>Rachel K. Jones, PhD</i>	
	Mechanism of Action .....	452
	Effectiveness .....	452
	Advantages .....	453
	Disadvantages and Cautions .....	453
	Special Issues .....	453
	Providing the Method .....	455
	User Instructions for Withdrawal .....	455
<b>16</b>	<b>Permanent Contraception</b> .....	459
	<i>Melody Y. Hou, MD, MPH, FACOG</i>	
	<i>Danielle Roncari, MD, MPH</i>	
	Fallopian Tube Surgery .....	460
	Vas Surgery .....	486

<i>Chapter</i>		<i>Page</i>
<b>17</b>	<b>Contraception after Pregnancy</b> .....	<b>511</b>
	<i>Kathy Irene Kennedy, DrPH, MA</i>	
	<i>Crystal Goldsmith, MD, MS</i>	
	Postpartum Infertility .....	513
	Lactational Infertility .....	513
	Contraceptive Benefits of Lactation .....	514
	Postpartum Sexuality .....	517
	Initiating Contraceptive Use Postpartum .....	518
	Breastfeeding: Advantages to the Infant .....	530
	Breastfeeding and HIV .....	530
	Breastfeeding: Effects on the Mother .....	531
	Instructions for and Information about Breastfeeding ..	532
<b>18</b>	<b>Contraception for Women with Medical Conditions</b> .....	<b>543</b>
	<i>Rebecca H. Allen, MD, MPH</i>	
	<i>Carrie A. Cwiak, MD, MPH</i>	
	The Safety of Contraceptive Methods .....	544
	Risks of Unintended Pregnancy .....	549
	CDC Medical Eligibility Criteria for Contraceptive Use .....	549
<b>19</b>	<b>Contraception in the Later Reproductive Years</b> .....	<b>561</b>
	<i>Amanda Black, MD, MPH</i>	
	<i>Anita L. Nelson, MD</i>	
	Changing Contraceptive Needs During the Later Reproductive Years .....	564
	Contraceptive Options During the Later Reproductive Years .....	565
	When Can Contraception be Reliably Stopped? .....	573
<b>20</b>	<b>Reproductive Tract Infections, Including HIV and Other Sexually Transmitted Infections</b> .....	<b>579</b>
	<i>Jeanne M. Marrazzo, MD, MPH</i>	
	<i>Ina U. Park MD, MS</i>	
	Magnitude and Risks of RTIs .....	580
	Transmission of RTIs .....	581
	RTI Risk Assessment, Prevention and Risk Behaviors .....	582
	Assessment, Diagnosis, and Treatment of RTIs .....	584
	Special Considerations Regarding RTI Evaluation in the Reproductive Health Setting .....	591

<i>Chapter</i>		<i>Page</i>
	Counseling About Safer Sex . . . . .	592
	Specific Concerns Related to HIV . . . . .	593
	Summary of Major Reproductive Tract Infections, Including HIV, by Syndrome . . . . .	597
	Consultation for Complex RTI in HIV-Positive Patients. . . . .	619
<b>21</b>	<b>Screening Women for Cervical, Ovarian, and Breast Cancer . . . . .</b>	<b>629</b>
	<i>Michael S. Policar, MD, MPH</i>	
	<i>George F. Sawaya, MD</i>	
	Cervical Cancer. . . . .	632
	Ovarian Cancer. . . . .	645
	Breast Cancer . . . . .	649
<b>22</b>	<b>Sexuality &amp; Contraception . . . . .</b>	<b>661</b>
	<i>Jenny A. Higgins, PhD, MPH</i>	
	<i>Patty Cason MS, FNP-BC</i>	
	Sexuality 101: Sexual Behavior in Social Contexts . . . .	663
	“Normal” Sexual Behaviors . . . . .	669
	Sexual Problems . . . . .	674
	The Sexual Acceptability of Contraceptive Methods. . .	677
	Summary . . . . .	691
	Tools & Further Resources . . . . .	692
<b>23</b>	<b>Mental Health and Contraception . . . . .</b>	<b>711</b>
	<i>Kelli Stidham Hall, PhD, MS, FNP</i>	
	<i>Julia R. Steinberg, PhD, MA</i>	
	The Potential Impact of Hormonal Contraception on Mood. . . . .	713
	Clinical Management of Depression in Reproductive Health Care Settings . . . . .	716
	Contraceptive Initiation and Management in the Context of Mental Health . . . . .	722
	Special Cases of Mental Health and Contraceptive Management . . . . .	730
	Conclusions. . . . .	735
<b>24</b>	<b>Pregnancy Testing and Assessment of Early Normal and Abnormal Pregnancy . . . . .</b>	<b>747</b>
	<i>Maureen K. Baldwin, MD, MPH</i>	
	<i>Alison B. Edelman, MD, MPH</i>	
	Essential Pregnancy Information for Everyone . . . . .	747
	Education and Counseling . . . . .	748

<i>Chapter</i>		<i>Page</i>
	Pregnancy Evaluation: Gestational Dating, History, Symptoms, Physical Exam, Laboratory Evaluation, Additional Screening . . . . .	750
	Human Chorionic Gonadotropin Hormone (hCG) Levels in Pregnancy, Pregnancy Testing, Pitfalls of Pregnancy Tests . . . . .	754
	Ultrasound in Very Early Pregnancy . . . . .	763
	Abnormal Pregnancy Assessment . . . . .	769
<b>25</b>	<b>Abortion . . . . .</b>	<b>779</b>
	<i>Siripanth Nippita, MD, MS</i>	
	<i>Maureen Paul, MD, MPH</i>	
	Legal Status of Abortion . . . . .	780
	The Public Health Impact of Legal Abortion . . . . .	782
	Characteristics of Individuals Who Obtain Abortions . . . . .	784
	Evaluation and Preparation of Patients for Abortion . . . . .	787
	Clinical Provision of Abortion Methods . . . . .	792
	Adjunctive Techniques . . . . .	806
	Managing Postabortion Adverse Events and Morbidity . . . . .	809
	Postabortion Contraception . . . . .	815
<b>26</b>	<b>Contraceptive Efficacy . . . . .</b>	<b>829</b>
	<i>James Trussell, PhD</i>	
	<i>Abigail R.A. Aiken, MD, MPH, PhD</i>	
	No Method . . . . .	830
	Typical Use of Withdrawal, Male Condom, Oral Contraceptive Pills, and Depo-Provera . . . . .	831
	Typical and Perfect Use of the Sponge . . . . .	832
	Typical and Perfect Use of the Diaphragm . . . . .	832
	Typical and Perfect Use of the Female Condom . . . . .	833
	Perfect Use of Withdrawal . . . . .	833
	Typical and Perfect Use of Spermicides . . . . .	833
	Typical and Perfect Use of Fertility Awareness-Based Methods . . . . .	835
	Perfect Use of the Male Condom . . . . .	835
	Perfect Use of Oral Contraceptive Pills, Depo-Provera, and Nexplanon, and Typical Use of Nexplanon . . . . .	836
	Typical and Perfect Use of Evra and Nuvaring . . . . .	837
	Typical and Perfect Use of Intrauterine Devices (IUDs) . . . . .	837

<i>Chapter</i>	<i>Page</i>
Typical and Perfect Use of Permanent Contraception . . . . .	838
Contraceptive Continuation . . . . .	838
Emergency Contraception . . . . .	839
The Lactational Amenorrhea Method (LAM) . . . . .	839
<i>Appendix</i>	<i>Page</i>
<b>1 Digital Resources for Health &amp; Medical Information . . . . .</b>	<b>929</b>
<i>Brian Nguyen, MD, MSCP</i>	
<i>Leo Han, MD, MPH</i>	
<b>Index . . . . .</b>	<b>951</b>